Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
P/B ratio for Kinnate Biopharma Inc. (KNTE)
P/B ratio as of 2023: 0.69
According to Kinnate Biopharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.69. At the end of 2022 the company had a P/B ratio of 1.20.
P/B ratio history for Kinnate Biopharma Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.69 |
| 2022 | 1.20 |
| 2021 | 2.42 |
| 2020 | 4.40 |
| 2019 | -96.71 |
| 2018 | 55.39 |